KAMPALA, Uganda
Kenya’s Health Cabinet Secretary, Mutahi Kagwe, yesterday warned Kenyans that there were no miracles in the acquisition of Covid vaccines.
The CS said the nationalisation of the Astrazeneca vaccines
by the Indian government has forced 93 countries around the world to look for
alternatives elsewhere.
“There are no miracles regarding the AstraZeneca vaccine.
We have to live with the current situation as we find alternatives. In any
case, we have until July to worry about the second dose,” the CS told the Star
last night.
He, however, assured those who took the first AstraZeneca
jab not to worry about any negative effect saying, “your immunity against the
disease is more than 60 per cent meaning that if you get the virus you are
likely to suffer fewer symptoms. No one will die because they did not get the
second dose”.
As a result of the shortage, the government has placed an
order of 30 million Johnson and Johnson doses, which will be delivered within a
year.
During a meeting by Africa’s health minister last Saturday,
Kagwe proposed that all the money raised via the Covax initiative be used to
pay for 200 million doses of Pfizer and another 210 doses of the Johnson and
Johnson vaccine.
“With this arrangement, Kenya will not pay anything and
will be able to easily get and vaccinate 30 million people with Johnson and
Johnson which is being manufactured in Africa and will be a single dose.
Vaccination centres gave May dates for the second dose
after eight weeks and the government revised that to June to cater for delays
in supply. Even that 12-week window is now in doubt.
The AstraZeneca vaccine manufacturer, the Serum Institute
of India, has said it can no longer give commitments for supply.
It has begun refunding monies it had received from
countries to ship doses.
The suspension of exports has created a shortfall of 90
million doses for Covax, 40 million affected in March and 50 million in April.
Head of vaccines deployment task force Willis Aklwale had
said some 2.5 million doses would arrive from India in early June. The earliest
supplies might resume in July.
The one million Kenyans who have received their first doses
will wait beyond the 12 weeks to receive their final doses.
Scientists still do not know what this means to their
immunity.
India has banned all vaccine exports due to its Covid-19 variant that is ravaging the country.
It is importing Sputnik V from Russia and has extended
vaccination campaign to people aged 18 years and below.
The suspension of exports has created a major shortfall in
doses for Covax, the WHO-backed plan for poor nations that Kenya relies on.
The Serum Institute had promised to supply Covax with one
billion doses of the AstraZeneca jab by March. It
had only shipped about 30 million doses to Covax when it halted supplies.
Kenya received 1.02 million doses under the Covax facility
in March, and an extra 100,000 doses from the Indian government.
"Our hope is now receiving part of the 60 million
stockpiles of the AstraZeneca vaccine doses in the United States," a
member of the vaccines' deployment task force told the Star on Tuesday.
The US stockpile is awaiting checks from the US Food and
Drug Administration before the doses are exported to the beneficiary countries.
Health CS Mutahi Kagwe said last week that they had
"reached out to the highest levels of the US government" for doses.
Global health expert Dr Benard Muia Tuesday said Kenya's
only way out of the virus crisis is masking, distancing and handwashing. He
suggested the country cannot depend on immunisation.
Dr Muia said getting the second consignment of the doses is
an exercise in futility.
“We are in trouble for sure, take it seriously as far as
vaccines is concerned because when we look at what is happening globally, we
developing countries are disadvantaged and we are not even sure of June,” Dr
Muia said.
“The dose we are talking about coming in June there is no
certainty in it, the only weapon on our hands we are left with is observing
these protocols,” he added.
The medic said that failure to get the second dose will
have a negative effect as it is supposed to play a critical role in immunity
boosting.
“The second booster is crucial so failure to get the second
dose means how the immunity was supposed to work will not be so because we are
not getting this booster. Of course, we vaccinated, the effect was there, the
immunity was triggered to produce antibodies but if we had a booster then
things would be far much better.”
World Health Organization Representative to Kenya Dr Rudi
Eggers has warned that the delays might open a door for new waves and variants.
"Almost all of those doses have now been given. And
due to the export restrictions from India, the next shipment has been delayed.
So we are currently in the situation where the supply of vaccine is the biggest
problem,” Dr Eggers said.
“So we do encourage countries to actually also in addition
to the Covax facility to source the vaccine bilaterally from the
manufacturer," he added.
A total of 917,068 Kenyans had been inoculated with their
first dose of the Covid-19 AstraZeneca vaccine by Monday.
Some 280,876 are those aged above 58 years, 160,947 are
healthcare workers, 143,684 are teachers, 77,417 are security officers while
254,144 are members of the public.
Head of Africa CDC John Nkengasong has warned that the
restrictions on vaccine exports would be catastrophic for the continent.
“Very clearly it worries me and very clearly the second
doses won’t come in time. It really means that everybody who has been
vaccinated until now will not get the second dose as planned,” Nkengasong said.
Kenya has also decided against getting a different type of
vaccine for the second dose because there is no scientific evidence that it is
effective or safe.
The country is looking to get Pfizer and Johnson and
Johnson vials to support vaccine roll out.
Acting Health director general Patrick Amoth said they will
be deployed immediately they land in the country.
The WHO will be meeting to deliberate on the Covid-19
vaccines patents and a waiver might help countries make and sell cheap
vaccines.
Dr Muia said that despite the progress on the matter, it
might take time for the idea to be actualised.
“Even if the patent comes into play, we are not going to
get those things soon and it is only South Africa who can produce those
vaccines so we are not yet out of the woods.”
No comments:
Post a Comment